Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21160967 | 1.00 | HRH3 (0.36) | HRH3KCNH2RECQLGAAHPGD | |
| SCHEMBL18768680 | 1.00 | HRH3 (0.36) | HRH3KCNH2RECQLGAAHPGD | |
| SCHEMBL6496552 | 1.00 | HRH3 (0.36) | HRH3KCNH2RECQLGAAHPGD | |
| SCHEMBL19649547 | 0.98 | RECQL (0.38) | HRH3KCNH2RECQLGAAHPGD | |
| SCHEMBL16627509 | 0.98 | RECQL (0.38) | HRH3KCNH2RECQLGAAHPGD | |
| SCHEMBL10996925 | 0.97 | HRH3 (0.36) | HRH3KCNH2GAAHPGDALDH1A1 | |
| SCHEMBL7021706 | 0.95 | HRH3 (0.35) | HRH3KCNH2RECQLGAAHPGD | |
| SCHEMBL16254919 | 0.95 | HRH3 (0.35) | HRH3KCNH2RECQLGAAHPGD | |
| SCHEMBL30341037 | 0.95 | HRH3 (0.35) | HRH3KCNH2RECQLGAAHPGD | |
| SCHEMBL5872327 | 0.95 | HRH3 (0.38) | HRH3KCNH2RECQLGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117003199-A | Dehydrogenation method and hydrogen production system using same | 现代自动车株式会社 | 2023-11-07 | — | — | CN | claimed |
| US-20230348266-A1 | DEHYDROGENATION METHOD AND HYDROGEN PRODUCTION SYSTEM USING THE SAME | HYUNDAI MOTOR COMPANY (KR) | 2023-11-02 | — | — | US | claimed |
| CN-116288752-A | Essential oil slow-release fiber and preparation method thereof | 上海汇素生物科技有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-114306276-B | Preparation method of multifunctional intestinal diagnosis and treatment preparation and product thereof | 上海纳米技术及应用国家工程研究中心有限公司 | 2023-05-30 | — | — | CN | claimed |
| WO-2021119464-A1 | COMPOSITIONS AND MODULAR NANO- AND MICROPARTICLES FOR THE DELIVERY OF VARIOUS AGENTS AND USE THEREOF | VERI NANO INC. (US) | 2021-06-17 | — | — | WO | claimed |
| CN-108607233-A | A kind of method that hypoxemia auxiliary prepares nanometer Chinese herbal medicine | 上海健康医学院 | 2018-10-02 | — | — | CN | claimed |
| WO-2012044963-A2 | PERFLUOROCARBONS FOR USE IN TREATING PRURITUS | OXYGEN BIOTHERAPEUTICS, INC. (US) | 2012-04-05 | — | — | WO | claimed |
| EP-2419392-A2 | EMULSIONS OF PERFLUOROCARBONS | Oxygen Biotherapeutics, Inc. (US) | 2012-02-22 | — | — | EP | claimed |
| WO-2010121082-A2 | EMULSIONS OF PERFLUOROCARBONS | OXYGEN BIOTHERAPEUTICS, INC. (US) | 2010-10-21 | — | — | WO | claimed |
| CN-117003199-A | Dehydrogenation method and hydrogen production system using same | 现代自动车株式会社 | 2023-11-07 | — | — | CN | disclosed |
| US-20230348266-A1 | DEHYDROGENATION METHOD AND HYDROGEN PRODUCTION SYSTEM USING THE SAME | HYUNDAI MOTOR COMPANY (KR) | 2023-11-02 | — | — | US | disclosed |
| CN-116288752-A | Essential oil slow-release fiber and preparation method thereof | 上海汇素生物科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-114306276-B | Preparation method of multifunctional intestinal diagnosis and treatment preparation and product thereof | 上海纳米技术及应用国家工程研究中心有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-114306653-A | Preparation method of PET/ultrasonic multifunctional intestinal tract contrast agent, product and application thereof | 上海纳米技术及应用国家工程研究中心有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20070197475-A1 | Medical emulsion of perfluororganic compounds and method for the production thereof | KUZNETSOVA, IRINA NIKOLAIEVNA (RU) | 2007-08-23 | — | — | US | disclosed |
| CN-1960975-A | Substituted pyridones as poly (ADP-ribose) polymerase (PARP) inhibitors | AVENTIS PHARMA INC (US) | 2007-05-09 | — | — | CN | disclosed |
| CN-1040436-C | Pharmaceuticals | SMITHKLINE BEECHAM PLC (GB) | 1998-10-28 | — | — | CN | disclosed |
| EP-0666736-A1 | STABILIZATION OF FLUOROCARBON EMULSIONS. | ALLIANCE PHARMA (US) | 1995-08-16 | — | — | EP | disclosed |
| WO-1994009625-A2 | STABILIZATION OF FLUOROCARBON EMULSIONS | ALLIANCE PHARMACEUTICAL CORP. (US) | 1994-05-11 | — | — | WO | disclosed |
| CN-1073173-A | Preparation method as the compound of 5-hydroxytryptamine receptor antagonist | SMITHKLINE BEECHAM PLC (GB) | 1993-06-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197475-A1 | Medical emulsion of perfluororganic compounds and method for the production thereof | PGF, PHOSPHO1, NEFM | HRH3 374/4885KCNH2 423/4885RECQL 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.